J. Goldman & Co’s Arvinas ARVN Stock Holding History

J. Goldman & Co’s Portfolio ARVN Stock Details ARVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-156,799	Closed	-$1.66M	–	711
2026 Q1	$1.66M	Buy	+156,799	New	+$1.94M	0.05%	351
2020 Q1	–	Sell	-12,452	Closed	-$512K	–	246
2019 Q4	$512K	Buy	+12,452	New	+$365K	0.04%	216

Other funds holding ARVN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

J. Goldman & Co's ARVN Position: Q2 2026 in Review

J. Goldman & Co sold out of Arvinas (ARVN) in Q2 2026, closing a stake of 156,799 shares — an estimated $1.66M sold.

J. Goldman & Co first reported a position in ARVN in Q4 2019 and held it in 2 quarters. The position peaked at $1.66M in Q1 2026. 201 funds tracked by Wall St. Rank hold ARVN as of Q2 2026.

J. Goldman & Co reported no remaining Arvinas position as of Q2 2026 after selling out during the quarter.
J. Goldman & Co sold 156,799 Arvinas shares in Q2 2026, an estimated $1.66M.
J. Goldman & Co first reported a position in Arvinas in Q4 2019 and held it in 2 quarters.
J. Goldman & Co's Arvinas position peaked at $1.66M in Q1 2026.
201 funds tracked by Wall St. Rank held Arvinas as of Q2 2026.

Based on J. Goldman & Co's 13F filing for Q2 2026, filed 14 Aug 2026.